Advantages of isovolemic hemodilution-red cell exchange therapy to prevent recurrent stroke in sickle cell anemia patients

Journal of Clinical Apheresis

Volumn 26, Issue 4, 2011, Pages 200-207

  Sarode, Ravi ^a   Matevosyan, Karén ^a   Rogers, Zora R ^a   Burner, James D ^a   Rutherford, Cynthia ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

chelation; iron overload; red cell exchange; therapeutic apheresis

Indexed keywords

DEFERASIROX; FERRITIN;

ADOLESCENT; ADULT; ADVERSE OUTCOME; ALLERGIC REACTION; ARTICLE; BRADYCARDIA; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG WITHDRAWAL; EXCHANGE BLOOD TRANSFUSION; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPOTENSION; IRON OVERLOAD; ISOVOLEMIC HEMODILUTION RED CELL EXCHANGE THERAPY; MALE; NAUSEA; PALLOR; PARESTHESIA; PATIENT COMPLIANCE; PATIENT SAFETY; RECURRENT DISEASE; SICKLE CELL ANEMIA; STROKE; SYNCOPE; TREATMENT DURATION;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; AUTOMATION, LABORATORY; BLOOD VOLUME; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE TRANSFUSION; FEMALE; HEMODILUTION; HUMANS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; STROKE; YOUNG ADULT;

EID: 80051546628     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20294     Document Type: Article

References (28)

1. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher D, Kutlar A, Nichols FT, Bonds DR, Brambilla D,. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339: 5-11. (Pubitemid 28304491)
2. Adams RJ, Brambilla D,. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005; 353: 2769-2778. (Pubitemid 43016816)
3. Lee MT, Piomelli S, Granger S, Miller ST, Harkness S, Brambilla DJ, Adams RJ,. Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results. Blood 2006; 108: 847-852. (Pubitemid 44154616)
4. Powars D, Wilson B, Imbus C, Pegelow C, Allen J,. The natural history of stroke in sickle cell disease. Am J Med 1978; 65: 461-471. (Pubitemid 8397664)
5. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, Wethers DL, Pegelow CH, Gill FM,. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91: 288-294. (Pubitemid 28018756)
6. Scothorn DJ, Price C, Schwartz D, Terrill C, Buchanan GR, Shurney W, Sarniak I, Fallon R, Chu JY, Pegelow CH, Wang W, Casella JF, Resar LS, Berman B, Adamkiewicz T, Hsu LL, Ohene-Frempong K, Smith-Whitley K, Mahoney D, Scott JP, Woods GM, Watanabe M, Debaun MR,. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 2002; 140: 348-354. (Pubitemid 34289713)
7. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR,. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992; 120: 360-366.
8. Portnoy BA, Herion JC,. Neurological manifestations in sickle-cell disease, with a review of the literature and emphasis on the prevalence of hemiplegia. Ann Intern Med 1972; 76: 643-652.
9. Craft S, Schatz J, Glauser TA, Lee B, DeBaun MR,. Neuropsychologic effects of stroke in children with sickle cell anemia. J Pediatr 1993; 123: 712-717. (Pubitemid 23316421)
10. Armstrong FD, Thompson RJ, Jr., Wang W, Zimmerman R, Pegelow CH, Miller S, Moser F, Bello J, Hurtig A, Vass K,. Cognitive functioning and brain magnetic resonance imaging in children with sickle Cell disease. Neuropsychology Committee of the Cooperative Study of Sickle Cell Disease. Pediatrics 1996; 97: 864-870. (Pubitemid 26170948)
11. Pegelow CH, Adams RJ, McKie V, Abboud M, Berman B, Miller ST, Olivieri N, Vichinsky E, Wang W, Brambilla D,. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126: 896-899.
12. Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E,. A modified transfusion program for prevention of stroke in sickle cell disease. Blood 1992; 79: 1657-1661.
13. Aygun B, McMurray MA, Schultz WH, Kwiatkowski JL, Hilliard L, Alvarez O, Heeney M, Kalinyak K, Lee MT, Miller S, Helms RW, Ware RE,. Chronic transfusion practice for children with sickle cell anaemia and stroke. Br J Haematol 2009; 145: 524-528.
14. Sarnaik S, Soorya D, Kim J, Ravindranath Y, Lusher J,. Periodic transfusions for sickle cell anemia and central nervous system infarction. Am J Dis Child 1979; 133: 1254-1257. (Pubitemid 10205404)
15. Russell MO, Goldberg HI, Hodson A, Kim HC, Halus J, Reivich M, Schwartz E,. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease. Blood 1984; 63: 162-169. (Pubitemid 14224534)
16. Hulbert ML, McKinstry RC, Lacey JL, Moran CJ, Panepinto JA, Thompson AA, Sarnaik SA, Woods GM, Casella JF, Inusa B, Howard J, Kirkham FJ, Anie KA, Mullin JE, Ichord R, Noetzel M, Yan Y, Rodeghier M, Debaun MR,. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 2011; 117: 772-779.
17. Wang WC, Kovnar EH, Tonkin IL, Mulhern RK, Langston JW, Day SW, Schell MJ, Wilimas JA,. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 1991; 118: 377-382.
18. Files B, Brambilla D, Kutlar A, Miller S, Vichinsky E, Wang W, Granger S, Adams RJ,. Longitudinal changes in ferritin during chronic transfusion: a report from the stroke prevention trial in sickle cell anemia (STOP). J Pediatr Hematol Oncol 2002; 24: 284-290. (Pubitemid 34506616)
19. Cabibbo S, Fidone C, Garozzo G, Antolino A, Manenti GO, Bennardello F, Licitra V, Calabrese S, Costantino F, Travali S, Distefano R, Bonomo P,. Chronic red blood cell exchange to prevent clinical complications in sickle cell disease. Transfus Apher Sci 2005; 32: 315-321. (Pubitemid 40804624)
20. Kim HC, Dugan NP, Silber JH, Martin MB, Schwartz E, Ohene-Frempong K, Cohen AR,. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994; 83: 1136-1142. (Pubitemid 24058566)
21. Adams DM, Schultz WH, Ware RE, Kinney TR,. Erythrocytapheresis can reduce iron overload and prevent the need for chelation therapy in chronically transfused pediatric patients. J Pediatr Hematol Oncol 1996; 18: 46-50. (Pubitemid 26048524)
22. Hilliard LM, Williams BF, Lounsbury AE, Howard TH,. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol 1998; 59: 28-35. (Pubitemid 28395003)
23. Abstracts of the 23rd Annual Meeting of the American Society for Apheresis, May 29-June 1, 2002, Orlando, Florida. J Clin Apher 2002; 17: 141-157.
24. Vichinsky EP, Luban NL, Wright E, Olivieri N, Driscoll C, Pegelow CH, Adams RJ,. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001; 41: 1086-1092. (Pubitemid 32848083)
25. Davies SC, Olatunji PO,. Blood transfusion in sickle cell disease. Vox Sang 1995; 68: 145-151.
26. Simon TL, Marcus CS, Myhre BA, Nelson EJ,. Effects of AS-3 nutrient-additive solution on 42 and 49 days of storage of red cells. Transfusion 1987; 27: 178-182. (Pubitemid 17101786)
27. Klein HG, Anstee DJ,. The transfusion of red cells. In:, Klein HG, editor. Mollison's Blood Transfusion in Clinical Medicine, 11th ed. Blackwell Science: Oxford, UK. 2007. pp 352-405.
28. Labus J, France C, Taylor B,. Vasovagal reactions in volunteer blood donors. Analyzing the predictive power of the medical fears survey. Int J Behav Med 2000; 7: 62-72. (Pubitemid 30642046)